Trulieve Cannabis (TRLV) Rallies +42.6% on NYSE Uplisting and $50 Million Buyback
Key Takeaways
- TRLV surged approximately 42.6% over the last 30 days, driven by a historic NYSE uplisting and a $50 million share repurchase program.
- The stock rallied roughly 79% during the most recent quarter, reflecting improving fundamentals and regulatory tailwinds.
- Trulieve became the first U.S. cannabis company to list on the New York Stock Exchange, a milestone that significantly boosted investor sentiment and institutional visibility.
- Q1 2026 results showed $287 million in revenue, a 59% gross margin, and positive net income, underscoring operational strength.
- Medical marijuana's reclassification to Schedule III removed the 280E tax burden, enhancing free cash flow and profitability.
- Analyst coverage has turned increasingly bullish, with multiple firms raising price targets and maintaining Buy ratings.
Trulieve Cannabis (TRLV): Company Background and Market Position
Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. The company cultivates, processes, manufactures, and retails a broad portfolio of cannabis products, including flower, edibles, vapes, concentrates, topicals, and accessories. Its brand portfolio spans names such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One. Trulieve operates dispensaries across Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania, with cultivation and processing facilities in several of those states. With approximately 5,000 employees and a market capitalization exceeding $2 billion, Trulieve is one of the largest and most scaled cannabis operators in the United States. Investors follow the stock closely due to its dominant Florida medical market position, expanding hub strategy, and sensitivity to federal cannabis policy developments.
Recent Stock Performance: +42.6% Over 30 Days and +79% for the Quarter
Over the 30-day period ending June 11, 2026, TRLV shares climbed from an adjusted closing price of $8.10 on May 12 to $11.55 on June 11, representing a gain of approximately 42.6%. The rally accelerated sharply in early June following the announcement of the company's NYSE uplisting and share buyback program. Daily trading volumes expanded significantly, with several sessions exceeding 1 million shares traded, reflecting heightened institutional and retail interest.
Zooming out to the quarterly timeframe, the stock's performance is even more striking. From an adjusted close of $6.44 on March 11, 2026, TRLV advanced roughly 79% to the June 11 level. The quarter was characterized by a steady upward grind through April, a brief consolidation in early May, and a powerful breakout in June. This multi-month trend was underpinned by improving financial results, regulatory progress, and growing confidence in the company's strategic direction.
Key Catalysts Behind the 30-Day Surge
The primary catalyst for the 30-day surge was Trulieve's historic transition to the New York Stock Exchange. On June 5, the company announced that its subordinate voting shares would begin trading under the ticker TRLV on June 10, making it the first U.S. cannabis company to list on the NYSE. The uplisting from the OTCQX market represented a major validation for the cannabis sector and opened the door to a broader universe of institutional investors who are restricted from trading over-the-counter securities.
Simultaneously, Trulieve's Board of Directors authorized a share repurchase program of up to $50 million, or approximately 5% of outstanding shares. The buyback announcement signaled management's confidence in the company's intrinsic value and commitment to returning capital to shareholders. These two events, occurring in rapid succession, created a powerful momentum shift that drove the stock sharply higher.
Additional support came from analyst activity. Alliance Global Partners raised its price target and reiterated a Buy rating, while Roth MKM and Haywood also maintained constructive outlooks. The company's Q1 2026 earnings, reported in early May, provided a fundamental backbone for the rally: revenue of $287 million, a 59% gross margin, positive net income of $2 million, and adjusted EBITDA of $100 million demonstrated that Trulieve could deliver profitability at scale. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Broader Drivers Behind Quarterly Gains
The broader quarterly advance was fueled by a confluence of regulatory, operational, and strategic developments. The most significant regulatory shift was the Drug Enforcement Administration's decision to reclassify state-regulated medical marijuana to Schedule III, effectively eliminating the onerous 280E tax provision that had previously prevented cannabis companies from deducting ordinary business expenses. This change immediately improved Trulieve's after-tax cash flow and earnings profile.
Operationally, Trulieve continued to execute its hub strategy, maintaining dominant market share in Florida while selectively expanding in states such as Georgia, Ohio, and Maryland. The company's domestication from British Columbia to Delaware, announced in May, further aligned its corporate structure with U.S. capital markets and removed a technical barrier to the NYSE listing. Throughout the quarter, investor sentiment toward cannabis stocks improved broadly, with peers such as GTBIF, CURA.TO, and VRNO.NE also experiencing upward momentum, though Trulieve's NYSE catalyst set it apart.
Using AI Tools to Analyze Volatile Sectors
As someone who follows fast-moving sectors like cannabis, I frequently review Tickeron’s Trending AI Robots page for a curated view of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies and timeframes. The Trending AI Robots section highlights only those bots demonstrating the most relevant and consistent performance metrics, allowing users to quickly identify strategies aligned with current market conditions. Whether focused on short-term momentum, swing trading, or longer-term trend following, these bots provide a quantitative edge. Exploring the Trending AI Robots page can help traders discover AI-driven approaches tailored to stocks experiencing significant price movements like TRLV.
What Investors Should Watch Next
Looking ahead, several factors will be critical for TRLV's trajectory. The company's next earnings report, estimated for early August 2026, will provide updated visibility on revenue growth, margin trends, and the ongoing impact of 280E tax relief. Investors should monitor any updates on the share repurchase program's execution pace and remaining authorization. Federal cannabis reform discussions, including potential progress on the SAFE Banking Act or broader descheduling efforts, remain a macro catalyst for the entire sector. On the competitive front, Trulieve's ability to defend its Florida market share while scaling newer markets will be closely watched. Additionally, the stock's elevated beta of 1.86 suggests continued sensitivity to broader market volatility and sector rotation. Analyst consensus currently stands at a Strong Buy with a 12-month price target of $21.00, implying significant upside from recent levels, though execution risks and regulatory uncertainty remain inherent to the cannabis industry.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRLV in downward trend: price dove below 50-day moving average on October 08, 2026
TRLV moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 39 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TRLV moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRLV as a result. In 72 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for TRLV turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 31 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 190 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 115 of 140 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.096) is normal, around the industry mean (43.873). P/E Ratio (120.482) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement